Today it was reported that the CMO of Invitae (NVTA), Robert Nussbaum, exercised options to buy 10,000 NVTA shares at $9.90 a share, for a total transaction value of $99K.
Following Robert Nussbaum’s last NVTA Buy transaction on May 16, 2018, the stock climbed by 16.3%. Following this transaction Robert Nussbaum’s holding in the company was increased by 6.11% to a total of $3.96 million.
See today’s analyst top recommended stocks >>
Based on Invitae’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $45.36 million and GAAP net loss of $29.84 million. In comparison, last year the company earned revenue of $25.4 million and had a GAAP net loss of $40.49 million. Currently, Invitae has an average volume of 2.21M. The Company has a Price to Book ratio of 10.6198.
Starting in September 2018, NVTA received 15 Buy ratings in a row. Four different firms, including Chardan Capital and J.P. Morgan, currently also have a Buy rating on the stock. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $22.50, reflecting a -1.2% downside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
